HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma.

Context.--ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA...

Full description

Bibliographic Details

Published in:	Archives of Pathology & Laboratory Medicine Vol. 140; no. 12; pp. 1345 - 1364
Main Authors:	Bartley, Angela N., Washington, Mary Kay, Ventura, Christina B., Ismaila, Nofisat, Colasacco, Carol, Benson III, Al B., Carrato, Alfredo, Gulley, Margaret L., Jain, Dhanpat, Kakar, Sanjay, Mackay, Helen J., Streutker, Catherine, Tang, Laura, Troxell, Megan, Ajani, Jaffer A.
Format:	algorithm pictorial tables/charts Journal Article
Published:	College of American Pathologists Dec2016
Online Access:	View this record in EBSCOhost